Physician profile
Kathy Hamon
NPI 1154312452
$1,972.28
in general payments reported to CMS, 2019-2025
31 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.26 · 2020: $20.89 · 2021: $182 · 2022: $34.33 · 2023: $546 · 2024: $703 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.56 | 2023-2025 | |
| Abbott Laboratories | $273.89 | 2021-2025 | Freestyle Libre 2 |
| Novo Nordisk INC | $191.28 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $157.83 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $133.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $116.66 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Mylan Specialty L.P. | $95.81 | 2021-2024 | Yupelri |
| Insulet Corporation | $65.95 | 2024 | Omnipod |
| Janssen Biotech, INC. | $61.85 | 2023-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $61.41 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.25 | 2024-2025 | Relistor, Xifaxan |
| Tandem Diabetes Care, INC. | $33.44 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $32.75 | 2023 | Qutenza |
| Nestle Healthcare Nutrition INC. | $32.25 | 2023 | |
| Dexcom, INC. | $30.30 | 2021-2023 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $25.13 | 2023 | Sublocade |
| Pfizer INC. | $24.88 | 2024 | |
| Recor Medical INC | $21.36 | 2025 | Paradise Ultrasound Renal Denervation System |
| Otsuka America Pharmaceutical, INC. | $20.94 | 2024 | Rexulti |
| Amarin Pharma, INC. | $20.89 | 2020 | |
| Astellas Pharma US INC | $20.66 | 2024 | Veozah |
| Amgen INC. | $19.05 | 2024 | Otezla, Repatha |
| Rhythm Pharmaceuticals, INC. | $17.75 | 2023 | Imcivree |
| Xeris Pharmaceuticals, INC. | $17.37 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $17.29 | 2025 | Korlym |
| Verona Pharma, INC. | $16.93 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.82 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $15.99 | 2024 | Camzyos |
| Aimmune Therapeutics, INC. | $15.58 | 2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $15.25 | 2023 | Strensiq |
| Eisai INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Hamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.